X4 Pharmaceuticals (XFOR) EV to FCF (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported EV to FCF for 8 consecutive years, with 18.99 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to FCF fell 2456.12% year-over-year to 18.99; the trailing twelve-month figure through Jun 2026 stood at 4.69 (down 2226.25% YoY), and the FY2025 full-year result was 0.56, up 207.19% from the prior year.
• EV to FCF declined to 18.99 in Q2 2026 per XFOR's latest filing, from 15.54 in the prior quarter.
• Across five years, EV to FCF topped out at 2.99 in Q4 2025 and bottomed at 245.99 in Q1 2024.
• Historically, EV to FCF has averaged 70.71 across 5 years, with a median of 47.76 in 2022.
• The sharpest annual moves came in 2025 and 2026: EV to FCF soared 241.48% in 2025, then plunged 24028.31% in 2026.
• Over 5 years, EV to FCF stood at 92.58 in 2022, then plunged by 70.05% to 157.43 in 2023, then soared by 98.66% to 2.11 in 2024, then jumped by 241.48% to 2.99 in 2025, then slumped by 735.23% to 18.99 in 2026.
• According to Business Quant data, EV to FCF over the past three periods registered 18.99, 15.54, and 2.99 for Q2 2026, Q1 2026, and Q4 2025 respectively.